Selected research
Industry Research
Human iPSCs Industry Research Report 2026
Market perspective
The global Human iPSCs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Human iPSCs market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Human iPSCs market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Human iPSCs market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Human iPSCs include Sumitomo Dainippon Pharma, ReproCELL, Pluricell Biotech, Ncardia, Fujifilm Holding Corporation (CDI), Fate Therapeutics, Inc, Cell Inspire Biotechnology and Astellas Pharma Inc, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Human iPSCs market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Human iPSCs.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Human iPSCs Market by Company
Sumitomo Dainippon Pharma
ReproCELL
Pluricell Biotech
Ncardia
Fujifilm Holding Corporation (CDI)
Fate Therapeutics, Inc
Cell Inspire Biotechnology
Astellas Pharma Inc
Human iPSCs Segment by Type
Skin
Blood Cells
Human iPSCs Segment by Application
Regenerative Medicine
Drug Development and Discovery
Academic Research
Toxicity Screening
Others
Human iPSCs Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Human iPSCs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Human iPSCs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Human iPSCs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Human iPSCs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Skin
- Blood Cells
Applications
- Regenerative Medicine
- Drug Development and Discovery
- Academic Research
- Toxicity Screening
- Others
Companies covered
- Sumitomo Dainippon Pharma
- ReproCELL
- Pluricell Biotech
- Ncardia
- Fujifilm Holding Corporation (CDI)
- Fate Therapeutics, Inc
- Cell Inspire Biotechnology
- Astellas Pharma Inc
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Human iPSCs by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Skin
- 2.2.3 Blood Cells
- 2.3 Human iPSCs by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Regenerative Medicine
- 2.3.3 Drug Development and Discovery
- 2.3.4 Academic Research
- 2.3.5 Toxicity Screening
- 2.3.6 Others
- 2.4 Assumptions and Limitations
3 Human iPSCs Breakdown Data by Type
- 3.1 Global Human iPSCs Historic Market Size by Type (2021-2026)
- 3.2 Global Human iPSCs Forecasted Market Size by Type (2027-2032)
4 Human iPSCs Breakdown Data by Application
- 4.1 Global Human iPSCs Historic Market Size by Application (2021-2026)
- 4.2 Global Human iPSCs Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Human iPSCs Market Perspective (2021-2032)
- 5.2 Global Human iPSCs Growth Trends by Region
- 5.2.1 Global Human iPSCs Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Human iPSCs Historic Market Size by Region (2021-2026)
- 5.2.3 Human iPSCs Forecasted Market Size by Region (2027-2032)
- 5.3 Human iPSCs Market Dynamics
- 5.3.1 Human iPSCs Industry Trends
- 5.3.2 Human iPSCs Market Drivers
- 5.3.3 Human iPSCs Market Challenges
- 5.3.4 Human iPSCs Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Human iPSCs Players by Revenue
- 6.1.1 Global Top Human iPSCs Players by Revenue (2021-2026)
- 6.1.2 Global Human iPSCs Revenue Market Share by Players (2021-2026)
- 6.2 Global Human iPSCs Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Human iPSCs Head Office and Area Served
- 6.4 Global Human iPSCs Players, Product Type & Application
- 6.5 Global Human iPSCs Manufacturers Established Date
- 6.6 Global Human iPSCs Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Human iPSCs Market Size (2021-2032)
- 7.2 North America Human iPSCs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Human iPSCs Market Size by Country (2021-2026)
- 7.4 North America Human iPSCs Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Human iPSCs Market Size (2021-2032)
- 8.2 Europe Human iPSCs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Human iPSCs Market Size by Country (2021-2026)
- 8.4 Europe Human iPSCs Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Human iPSCs Market Size (2021-2032)
- 9.2 Asia-Pacific Human iPSCs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Human iPSCs Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Human iPSCs Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Human iPSCs Market Size (2021-2032)
- 10.2 South America Human iPSCs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Human iPSCs Market Size by Country (2021-2026)
- 10.4 South America Human iPSCs Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Human iPSCs Market Size (2021-2032)
- 11.2 Middle East & Africa Human iPSCs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Human iPSCs Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Human iPSCs Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Sumitomo Dainippon Pharma
- 12.1.1 Sumitomo Dainippon Pharma Company Information
- 12.1.2 Sumitomo Dainippon Pharma Business Overview
- 12.1.3 Sumitomo Dainippon Pharma Revenue in Human iPSCs Business (2021-2026)
- 12.1.4 Sumitomo Dainippon Pharma Human iPSCs Product Portfolio
- 12.1.5 Sumitomo Dainippon Pharma Recent Developments
- 12.2 ReproCELL
- 12.2.1 ReproCELL Company Information
- 12.2.2 ReproCELL Business Overview
- 12.2.3 ReproCELL Revenue in Human iPSCs Business (2021-2026)
- 12.2.4 ReproCELL Human iPSCs Product Portfolio
- 12.2.5 ReproCELL Recent Developments
- 12.3 Pluricell Biotech
- 12.3.1 Pluricell Biotech Company Information
- 12.3.2 Pluricell Biotech Business Overview
- 12.3.3 Pluricell Biotech Revenue in Human iPSCs Business (2021-2026)
- 12.3.4 Pluricell Biotech Human iPSCs Product Portfolio
- 12.3.5 Pluricell Biotech Recent Developments
- 12.4 Ncardia
- 12.4.1 Ncardia Company Information
- 12.4.2 Ncardia Business Overview
- 12.4.3 Ncardia Revenue in Human iPSCs Business (2021-2026)
- 12.4.4 Ncardia Human iPSCs Product Portfolio
- 12.4.5 Ncardia Recent Developments
- 12.5 Fujifilm Holding Corporation (CDI)
- 12.5.1 Fujifilm Holding Corporation (CDI) Company Information
- 12.5.2 Fujifilm Holding Corporation (CDI) Business Overview
- 12.5.3 Fujifilm Holding Corporation (CDI) Revenue in Human iPSCs Business (2021-2026)
- 12.5.4 Fujifilm Holding Corporation (CDI) Human iPSCs Product Portfolio
- 12.5.5 Fujifilm Holding Corporation (CDI) Recent Developments
- 12.6 Fate Therapeutics, Inc
- 12.6.1 Fate Therapeutics, Inc Company Information
- 12.6.2 Fate Therapeutics, Inc Business Overview
- 12.6.3 Fate Therapeutics, Inc Revenue in Human iPSCs Business (2021-2026)
- 12.6.4 Fate Therapeutics, Inc Human iPSCs Product Portfolio
- 12.6.5 Fate Therapeutics, Inc Recent Developments
- 12.7 Cell Inspire Biotechnology
- 12.7.1 Cell Inspire Biotechnology Company Information
- 12.7.2 Cell Inspire Biotechnology Business Overview
- 12.7.3 Cell Inspire Biotechnology Revenue in Human iPSCs Business (2021-2026)
- 12.7.4 Cell Inspire Biotechnology Human iPSCs Product Portfolio
- 12.7.5 Cell Inspire Biotechnology Recent Developments
- 12.8 Astellas Pharma Inc
- 12.8.1 Astellas Pharma Inc Company Information
- 12.8.2 Astellas Pharma Inc Business Overview
- 12.8.3 Astellas Pharma Inc Revenue in Human iPSCs Business (2021-2026)
- 12.8.4 Astellas Pharma Inc Human iPSCs Product Portfolio
- 12.8.5 Astellas Pharma Inc Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst